Assessing Drug-Smoking Interactions Using PBPK Modeling
The prevalence of cigarette smoking remains high globally despite abundant evidence showing that it isn't…
Certara2016 年 7 月 29 日
Status of QSP Modeling in the Pharmaceutical Industry
A primary cause of failures in pharmaceutical research and development (R&D) has been attributed to…
Certara2016 年 7 月 6 日
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-mediated Clearances
Rosuvastatin is a substrate of choice in clinical studies of organic anion-transporting polypeptide (OATP)1B1- and…
Certara2016 年 7 月 1 日
Development of a Permeability-limited Model of the Human Brain and Cerebrospinal Fluid (CSF) to Integrate Known Physiological and Biological Knowledge: Estimating Time Varying CSF Drug Concentrations and Their Variability Using In Vitro Data
A 4-compartment permeability-limited brain (4Brain) model consisting of brain blood, brain mass, cranial and spinal…
Certara2016 年 6 月 1 日
Prediction of Drug-drug Interactions Arising From CYP3A Induction Using a Physiologically-based Dynamic Model
Using physiologically-based pharmacokinetic modeling, we predicted the magnitude of drug-drug interactions (DDIs) for studies with…
Certara2016 年 6 月 1 日
Recent Advances in Development and Application of Physiologically-based Pharmacokinetic (PBPK) Models: A Transition from Academic Curiosity to Regulatory Acceptance
There is a renewed surge of interest in applications of physiologically-based pharmacokinetic (PBPK) models by the…
Certara2016 年 4 月 14 日
Inside the Mind of Pharmacometrics Pioneer, Professor Malcolm Rowland
Officially, Prof. Malcolm Rowland has retired. This scientific pioneer has been helping lay the foundation…
Certara2016 年 2 月 23 日
